跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 113 条关于
“XIAP”
全部
113
临床试验
78
药物
25
机构
1
资讯
9
上个月
Nippon Shinyaku Exercises Option for AB2 Bio's Tadekinig Alfa, Securing U.S. Commercialization Rights for Rare Autoinflammatory Diseases
上个月
Nippon Shinyaku Exercises $30 Million U.S. Commercialization Option for AB2 Bio's Tadekinig Alfa in Ultra-Rare Pediatric Hyperinflammatory Syndrome
去年
AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa
去年
Ascentage Pharma Unveils Promising Preclinical Data for Five Oncology Drug Candidates at AACR 2025
3个月前
FDA Grants Rare Pediatric Disease and Orphan Drug Designations to FL118 for Osteosarcoma Treatment
2个月前
Advances in Targeting IL-1 Family Cytokines for Inflammatory Disease Treatment
去年
Cadrenal Therapeutics Acquires eXIthera's Factor XIa Inhibitor Portfolio in $15M Deal
4个月前
Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance AI-Driven Drug Discovery Platform
10个月前
OCEANIC-STROKE Phase 3 Trial Advances Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention